Brilinta is a p2y12 platelet inhibitor indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (acs) or a history of myocardial infarction (mi). For at least the first 12 months following acs, it is superior to clopidogrel. Brilinta also reduces the rate of stent thrombosis in patients who have been stented for treatment of acs.
Disclaimer: CTX Lifesciences respects patent laws and conventions of pharmaceuticals as applicable in different countries.
API/Substances covered by patent are not offered to the countries where the patent law is in force. However, the final responsibility lies with the customer.